Ngā hua rapu - Annette Hasenburg
- E whakaatu ana i te 1 - 20 hua o te 32
- Haere ki te Whārangi Whai Ake
-
1
Cancer and Pregnancy: A Comprehensive Review mā Roxana Schwab, Katharina Anić, Annette Hasenburg
I whakaputaina 2021Revisão -
2
-
3
-
4
-
5
-
6
-
7
-
8
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substud... mā Peyman Hadji, M. Ziller, D. G. Kieback, W. Dornoff, H.W. Tessen, Thomas Menschik, Joachim Kuck, F. Melchert, Annette Hasenburg
I whakaputaina 2009Artigo -
9
Development and evaluation of a “simulator-based” ultrasound training program for university teaching in obstetrics and gynecology–the prospective GynSim study mā Johannes Weimer, Florian Recker, Annette Hasenburg, Holger Buggenhagen, Karla Karbach, Lia Beer, Andreas Weimer, Lina Judit Schiestl, Liv Lorenz, Roman Kloeckner, Anna Dionysopoulou
I whakaputaina 2024Artigo -
10
Histopathological biomarkers in squamous cell carcinoma of the vulva: the prognostic relevance of tumor-infiltrating lymphocytes (TILs)—a retrospective study of 157 cases mā Gilbert Georg Klamminger, Meletios P. Nigdelis, Yaman Degirmenci, Bashar Haj Hamoud, Erich Solomayer, Laura Schnöder, Bernd Holleczek, Marcus Schmidt, Annette Hasenburg, Mathias Wagner
I whakaputaina 2025Artigo -
11
Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes mā M. Stumpf, Annette Hasenburg, M-O Riener, Uta Jütting, Cheng Wang, Yijun Shen, Marzenna Orlowska‐Volk, Paul Fisch, Zhishan Wang, G. Gitsch, Martin Werner, Silke Laßmann
I whakaputaina 2009Artigo -
12
Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis mā Roxana Schwab, Lina Judit Schiestl, Lorena Cascant Ortolano, Philip Herbert Klecker, Mona Wanda Schmidt, Katrin Almstedt, Anne-Sophie Heimes, Walburgis Brenner, Kathrin Stewen, Marcus Schmidt, Annette Hasenburg
I whakaputaina 2024Revisão -
13
Heterogeneous<i>HER2</i>Gene Amplification mā Alastair I. Bartlett, Jane Starcyznski, Tammy Robson, Alex MacLellan, Fiona Campbell, Cornelis J.�H. van de Velde, Annette Hasenburg, Christos Markopoulos, Caroline Seynaeve, Daniel Rea, John M.S. Bartlett
I whakaputaina 2011Artigo -
14
Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer mā Keying Xu, Jane Bayani, Elizabeth Mallon, Gregory R. Pond, Tammy Piper, Annette Hasenburg, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Cornelis J.�H. van de Velde, Daniel Rea, John M.S. Bartlett
I whakaputaina 2022Artigo -
15
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and e... mā Klaus Baumann, Andreas du Bois, Werner Meier, Jörn Rau, Pauline Wimberger, Jalid Sehouli, Christian Kurzeder, Felix Hilpert, Annette Hasenburg, Ulrich Canzler, Lars Hanker, Peter Hillemanns, Barbara Richter, K. Wollschlaeger, T. Dewitz, Dirk Bauerschlag, Uwe Wagner
I whakaputaina 2012Artigo -
16
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors mā Maxim Kebenko, Marie-Elisabeth Goebeler, M. Wolf, Annette Hasenburg, Ruth Seggewiss‐Bernhardt, Barbara Ritter, Beate Rautenberg, Djordje Atanackovic, Andrea Kratzer, James B. Rottman, Matthias Friedrich, Eva Vieser, Stefanie Elm, Ingrid Patzak, Dorothea Wessiepe, Sabine Stienen, Walter Fiedler
I whakaputaina 2018Artigo -
17
Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population mā Marcus Schmidt, Veronika Weyer‐Elberich, Jan G. Hengstler, Anne-Sophie Heimes, Katrin Almstedt, Aslihan Gerhold‐Ay, Antje Lebrecht, Marco Johannes Battista, Annette Hasenburg, Uğur Şahin, Konstantine T. Kalogeras, Pirkko‐Liisa Kellokumpu‐Lehtinen, George Fountzilas, Ralph M. Wirtz, Heikki Joensuu
I whakaputaina 2018Artigo -
18
European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery mā Christina Fotopoulou, François Planchamp, Tugce Aytulu, Luis Chiva, Alessandro Cina, Önder Ergönül, Anna Fagotti, Dimitrios Haidopoulos, Annette Hasenburg, Cathy Hughes, Paweł Knapp, Philippe Morice, Stephanie Schneider, Jalid Sehouli, Emmanouil Stamatakis, Stéphanie Suria, Çağatay Taşkıran, Ralf Ulrich Trappe, Jeremy Campbell
I whakaputaina 2021Artigo -
19
Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer mā Katrin Almstedt, Lisa Krauthauser, Franziska Kappenberg, Daniel‐Christoph Wagner, Anne-Sophie Heimes, Marco Johannes Battista, Katharina Anić, Slavomir Krajnak, Antje Lebrecht, Roxana Schwab, Walburgis Brenner, W. Weikel, Jörg Rahnenführer, Jan G. Hengstler, Wilfried Roth, Annette Hasenburg, Kathrin Stewen, Marcus Schmidt
I whakaputaina 2023Artigo -
20
Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study mā John M.S. Bartlett, Kenneth J. Bloom, Tammy Piper, Thomas J. Lawton, Cornelis J.�H. van de Velde, Douglas T. Ross, Brian Z. Ring, Robert S. Seitz, Rodney A. Beck, Annette Hasenburg, D. G. Kieback, Hein Putter, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Daniel Rea
I whakaputaina 2012Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Internal medicine
Cancer
Oncology
Breast cancer
Biology
Ovarian cancer
Gynecology
Pathology
Randomized controlled trial
Surgery
Genetics
Paleontology
Adverse effect
Exemestane
Stage (stratigraphy)
Tamoxifen
Cancer research
Chemotherapy
Clinical endpoint
Clinical trial
Confidence interval
Environmental health
General surgery
Immunohistochemistry
Intensive care medicine
Population
Sociology
Vulvar cancer
Adjuvant